INFbeta therapy for COVID-19 (Record no. 76013)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02042nim a2200505 a 4500 |
| 001 - CONTROL NUMBER | |
| control field | HST8172 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | UkLoHST |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o h |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nna|||||||| |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | sr |mnnnnnzne| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 200604s2020 enk|||||o||h||||||||eng d |
| 028 50 - PUBLISHER NUMBER | |
| Publisher number | 8172 |
| Source | Henry Stewart Talks |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (UkLoHST)4301 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | UkLoHST |
| Language of cataloging | eng |
| Transcribing agency | UkLoHST |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Holgate, S. T. |
| Relator code | spk |
| 245 10 - TITLE STATEMENT | |
| Title | INFbeta therapy for COVID-19 |
| Medium | [electronic resource] : |
| Remainder of title | the new SNG001 drug / |
| Statement of responsibility, etc. | Stephen Holgate. |
| 246 3# - VARYING FORM OF TITLE | |
| Title proper/short title | INFβ therapy for COVID-19 : the new SNG001 drug |
| 246 3# - VARYING FORM OF TITLE | |
| Title proper/short title | Interferon-beta therapy for COVID-19 : the new SNG001 drug |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc. | London : |
| Name of publisher, distributor, etc. | Henry Stewart Talks, |
| Date of publication, distribution, etc. | 2020. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (1 streaming audio file (10 min.)). |
| 490 1# - SERIES STATEMENT | |
| Series statement | Interviews on Covid-19, |
| International Standard Serial Number | 2056-452X |
| 500 ## - GENERAL NOTE | |
| General note | Audio interview. |
| 500 ## - GENERAL NOTE | |
| General note | Title from title frames. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Contents: Why INFβ was chosen as a therapy for COVID-19 -- Previous use of INFβ by inhalation -- Safety of INFβ as a therapy -- SNG001 mode of delivery -- SNG001 clinical trials and future prospects. |
| 506 ## - RESTRICTIONS ON ACCESS NOTE | |
| Terms governing access | Access restricted to subscribers. |
| 538 ## - SYSTEM DETAILS NOTE | |
| System details note | Mode of access: World Wide Web. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Antiviral agents |
| General subdivision | Development. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Clinical trials. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Coronavirus infections |
| General subdivision | Chemotherapy. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | COVID-19 (Disease) |
| General subdivision | Treatment. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Interferon. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Antiviral Agents |
| General subdivision | administration & dosage. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Clinical Trials as Topic. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Coronavirus infections. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | COVID-19 |
| General subdivision | drug therapy. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Drug Delivery Systems. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Interferon-beta |
| General subdivision | administration & dosage. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Interferon-beta |
| General subdivision | therapeutic use. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Nebulizers and Vaporizers. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | SARS-CoV-2. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Treatment Outcome. |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Henry Stewart talks. |
| Name of part/section of a work | Biomedical & life sciences collection. |
| -- | Interviews on Covid-19. |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://hstalks.com/bs/4301">https://hstalks.com/bs/4301</a> |
| 856 42 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://hstalks.com/bs/p/1060/">https://hstalks.com/bs/p/1060/</a> |
| Materials specified | Series |
No items available.